Edition:
United Kingdom

People: Stryker Corp (SYK.N)

SYK.N on New York Stock Exchange

214.10USD
9:10pm BST
Change (% chg)

$-4.17 (-1.91%)
Prev Close
$218.27
Open
$218.20
Day's High
$219.60
Day's Low
$212.80
Volume
391,939
Avg. Vol
298,501
52-wk High
$222.00
52-wk Low
$144.77

Scannell, Timothy 

Mr. Timothy J. Scannell is President, Chief Operating Officer of the Company effective August 1, 2018. He began his career with Stryker in 1990 with our Endoscopy division, where he served in various sales and marketing leadership roles. Mr. Scannell progressed to the position of Executive Vice President, overseeing sales, marketing and operations. In 2001, he was appointed Vice President and General Manager of our Biotech division. In 2003, he was named Vice President and General Manager of our Spine division and was later promoted to President of Spine. In 2009, he was appointed to the position of Group President and initially was responsible for the Spine and Endoscopy divisions. Over time, the role expanded to include MedSurg and Neurotechnology, with each of the group’s divisional leaders reporting to him. He serves on the Board of Directors for Insulet Corporation, whose OmniPod®Insulin Management System helps to improve the lives of people with diabetes.

Basic Compensation

Total Annual Compensation, USD 691,250
Restricted Stock Award, USD 3,380,330
Long-Term Incentive Plans, USD --
All Other, USD 2,560,600
Fiscal Year Total, USD 6,632,180

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 85,000 8,021,450.00
Name Fiscal Year Total

Kevin Lobo

13,911,100

Timothy Scannell

6,632,180

Glenn Boehnlein

3,788,570

Viju Menon

4,394,190

M. Kathryn Fink

--

Bijoy Sagar

--
As Of  31 Dec 2018